Douglas M. Willis

Array ( [id] => 20433232 [patent_doc_number] => 12503456 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-23 [patent_title] => Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors [patent_app_type] => utility [patent_app_number] => 18/628280 [patent_app_country] => US [patent_app_date] => 2024-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6665 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667490 [patent_doc_number] => 12180218 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-31 [patent_title] => Substituted pyrimido[4,5-b]indoles as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/627412 [patent_app_country] => US [patent_app_date] => 2024-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9995 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18627412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19910240 [patent_doc_number] => 12286436 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-29 [patent_title] => Substituted pyrimido[4,5-b]indoles as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/627407 [patent_app_country] => US [patent_app_date] => 2024-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6345 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 249 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18627407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403572 [patent_doc_number] => 20240287083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => SOLUTION REFLUX PROCESS FOR MAKING SUBSTITUTED IMIDAZO PYRAZOLES [patent_app_type] => utility [patent_app_number] => 18/624178 [patent_app_country] => US [patent_app_date] => 2024-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18624178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19642882 [patent_doc_number] => 20240417402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES [patent_app_type] => utility [patent_app_number] => 18/623738 [patent_app_country] => US [patent_app_date] => 2024-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18623738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20433249 [patent_doc_number] => 12503474 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-23 [patent_title] => Substituted pyrrolo[1,2-b]pyridazines as anthelmintics [patent_app_type] => utility [patent_app_number] => 18/622428 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39515 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18622428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403577 [patent_doc_number] => 20240287088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => EGFR INHIBITOR POLYMORPH FORMS [patent_app_type] => utility [patent_app_number] => 18/614458 [patent_app_country] => US [patent_app_date] => 2024-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18614458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403577 [patent_doc_number] => 20240287088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => EGFR INHIBITOR POLYMORPH FORMS [patent_app_type] => utility [patent_app_number] => 18/614458 [patent_app_country] => US [patent_app_date] => 2024-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18614458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528116 [patent_doc_number] => 20240352018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG [patent_app_type] => utility [patent_app_number] => 18/441757 [patent_app_country] => US [patent_app_date] => 2024-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528116 [patent_doc_number] => 20240352018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG [patent_app_type] => utility [patent_app_number] => 18/441757 [patent_app_country] => US [patent_app_date] => 2024-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19512045 [patent_doc_number] => 20240343731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION [patent_app_type] => utility [patent_app_number] => 18/437153 [patent_app_country] => US [patent_app_date] => 2024-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18437153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19512045 [patent_doc_number] => 20240343731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION [patent_app_type] => utility [patent_app_number] => 18/437153 [patent_app_country] => US [patent_app_date] => 2024-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18437153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638056 [patent_doc_number] => 12168656 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-17 [patent_title] => Process for making (e)-7-(4-((5-((2-chlorobenzylidene)amino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid [patent_app_type] => utility [patent_app_number] => 18/434620 [patent_app_country] => US [patent_app_date] => 2024-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3778 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18434620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432452 [patent_doc_number] => 20240300950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL][PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL[METHYL]-2-PYRIDINECARBOXAMIDE AS A COVALENT INHIBITOR OF MENIN-MLL INTERACTION [patent_app_type] => utility [patent_app_number] => 18/427226 [patent_app_country] => US [patent_app_date] => 2024-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345165 [patent_doc_number] => 20240254128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS [patent_app_type] => utility [patent_app_number] => 18/423972 [patent_app_country] => US [patent_app_date] => 2024-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38174 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18423972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20270795 [patent_doc_number] => 12440560 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Substituted pyrimidines as vaccine adjuvants [patent_app_type] => utility [patent_app_number] => 18/420017 [patent_app_country] => US [patent_app_date] => 2024-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8004 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528126 [patent_doc_number] => 20240352028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C [patent_app_type] => utility [patent_app_number] => 18/416739 [patent_app_country] => US [patent_app_date] => 2024-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18416739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20341865 [patent_doc_number] => 12465580 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Substituted fatty acids for treating non-alcoholic steatohepatitis [patent_app_type] => utility [patent_app_number] => 18/414988 [patent_app_country] => US [patent_app_date] => 2024-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 6159 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18414988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521068 [patent_doc_number] => 12122775 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-10-22 [patent_title] => Substituted pyrido[4,3-e]pyrrolo[1,2-a]pyrazines as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/413246 [patent_app_country] => US [patent_app_date] => 2024-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9215 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18413246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418357 [patent_doc_number] => 20240294480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO [patent_app_type] => utility [patent_app_number] => 18/414456 [patent_app_country] => US [patent_app_date] => 2024-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 336 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18414456 [rel_patent_id] =>[rel_patent_doc_number] =>)